{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:22:13Z","timestamp":1788956533005,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fujian Provincial Natural Science Foundation of China","award":["2022J011489"],"award-info":[{"award-number":["2022J011489"]}]},{"name":"Fujian Provincial Natural Science Foundation of China","award":["2023J011876"],"award-info":[{"award-number":["2023J011876"]}]},{"name":"Startup Fund for scientific research of Fujian Medical University","award":["2021QH1210"],"award-info":[{"award-number":["2021QH1210"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11596-025-00076-6","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T02:32:50Z","timestamp":1751855570000},"page":"831-840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dapagliflozin Suppressed Cuproptosis and Myocardial Fibrosis in Myocardial Infarction Through HIF-1\u03b1\/TGF-\u03b2 Pathway"],"prefix":"10.1007","volume":"45","author":[{"given":"Yu-ze","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-min","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3131-1922","authenticated-orcid":false,"given":"Yan-qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"issue":"4","key":"76_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pathophys.2018.04.003","volume":"25","author":"D Gabriel-Costa","year":"2018","unstructured":"Gabriel-Costa D. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiol. 2018;25(4):277\u2013284.","journal-title":"Pathophysiol."},{"issue":"1","key":"76_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ehf2.13144","volume":"8","author":"D Jen\u010da","year":"2021","unstructured":"Jen\u010da D, Melenovsk\u00fd V, Stehlik J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8(1):222\u2013237.","journal-title":"ESC Heart Fail."},{"issue":"2","key":"76_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jjcc.2022.07.003","volume":"81","author":"Y Saito","year":"2023","unstructured":"Saito Y, Oyama K, Tsujita K, et al. Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond. J Cardiol. 2023;81(2):168\u2013178.","journal-title":"J Cardiol."},{"issue":"1","key":"76_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni L, Yuan C, Chen G, et al. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19(1):98.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"76_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50050","volume":"7","author":"HC Pan","year":"2024","unstructured":"Pan HC, Chen JY, Chen HY, et al. Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease. JAMA Netw Open. 2024;7(1):e2350050.","journal-title":"JAMA Netw Open."},{"issue":"12","key":"76_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u2013772.","journal-title":"Nat Rev Cardiol."},{"issue":"7","key":"76_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","volume":"20","author":"M Packer","year":"2023","unstructured":"Packer M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol. 2023;20(7):443\u2013462.","journal-title":"Nat Rev Cardiol."},{"issue":"9","key":"76_CR8","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","volume":"28","author":"PS Jhund","year":"2022","unstructured":"Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28(9):1956\u20131964.","journal-title":"Nat Med."},{"issue":"5","key":"76_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cmet.2019.10.008","volume":"30","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Verma S, Braunwald E. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metab. 2019;30(5):847\u2013849.","journal-title":"Cell Metab."},{"key":"76_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111038","volume":"125","author":"X Zhao","year":"2023","unstructured":"Zhao X, Liu Y, Han X, et al. Dapagliflozin attenuates the vulnerability to atrial fibrillation in rats with lipopolysaccharide-induced myocardial injury. Int Immunopharmacol. 2023;125:111038.","journal-title":"Int Immunopharmacol."},{"issue":"11","key":"76_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.clinthera.2024.06.010","volume":"46","author":"P Karakasis","year":"2024","unstructured":"Karakasis P, Fragakis N, Kouskouras K, et al. Sodium-glucose cotransporter-2 inhibitors in patients with acute coronary syndrome: a modern cinderella? Clin Ther. 2024;46(11):841-850.","journal-title":"Clin Ther."},{"issue":"27","key":"76_CR12","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.2174\/0113816128304097240529053538","volume":"30","author":"P Karakasis","year":"2024","unstructured":"Karakasis P, Patoulias D, Kassimis G, et al. Therapeutic potential of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with acute coronary syndrome: a review of clinical evidence. Curr Pharm Des. 2024;30(27):2109\u20132119.","journal-title":"Curr Pharm Des."},{"issue":"1","key":"76_CR13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","volume":"7","author":"L Chen","year":"2022","unstructured":"Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Ther. 2022;7(1):378.","journal-title":"Signal Transduct Target Ther."},{"issue":"8","key":"76_CR14","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1080\/15548627.2023.2200554","volume":"19","author":"Q Xue","year":"2023","unstructured":"Xue Q, Kang R, Klionsky DJ, et al. Copper metabolism in cell death and autophagy. Autophagy. 2023;19(8):2175\u20132195.","journal-title":"Autophagy."},{"issue":"8","key":"76_CR15","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41423-022-00866-1","volume":"19","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang L, Zhou F. Cuproptosis: a new form of programmed cell death. Cell Mol Immunol. 2022;19(8):867\u2013868.","journal-title":"Cell Mol Immunol."},{"issue":"4","key":"76_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41418-023-01125-0","volume":"30","author":"C Xiong","year":"2023","unstructured":"Xiong C, Ling H, Hao Q, et al. Cuproptosis: p53-regulated metabolic cell death? Cell Death Differ. 2023;30(4):876\u2013884.","journal-title":"Cell Death Differ."},{"issue":"3","key":"76_CR17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s11418-024-01781-7","volume":"78","author":"X Fang","year":"2024","unstructured":"Fang X, Ji Y, Li S, et al. Paeoniflorin attenuates cuproptosis and ameliorates left ventricular remodeling after AMI in hypobaric hypoxia environments. J Nat Med. 2024;78(3):664\u2013676.","journal-title":"J Nat Med."},{"issue":"2","key":"76_CR18","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3390\/ijms24021667","volume":"24","author":"S Huo","year":"2023","unstructured":"Huo S, Wang Q, Shi W, et al. ATF3\/SPI1\/SLC31A1 Signaling Promotes Cuproptosis Induced by Advanced Glycosylation End Products in Diabetic Myocardial Injury. Int J Mol Sci. 2023;24(2):1667.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"76_CR19","doi-asserted-by":"publisher","first-page":"9887","DOI":"10.1038\/s41598-019-46402-6","volume":"9","author":"R Shibusawa","year":"2019","unstructured":"Shibusawa R, Yamada E, Okada S, et al. Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death. Sci Rep. 2019;9(1):9887.","journal-title":"Sci Rep."},{"issue":"2","key":"76_CR20","first-page":"1505","volume":"15","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Liu Z, Zhang H. Astragaloside protects myocardial cells from apoptosis through suppression of the TLR4\/NF-\u03baB signaling pathway. Exp Ther Med. 2018;15(2):1505\u20131509.","journal-title":"Exp Ther Med."},{"key":"76_CR21","doi-asserted-by":"publisher","first-page":"104274","DOI":"10.1016\/j.ebiom.2022.104274","volume":"85","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Meng D, Li F, et al. Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling. eBioMedicine. 2022;85:104274.","journal-title":"eBioMedicine."},{"issue":"5","key":"76_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41419-020-2542-9","volume":"11","author":"Y Guo","year":"2020","unstructured":"Guo Y, Yu Y, Hu S, et al. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. Cell Death Dis. 2020;11(5):349.","journal-title":"Cell Death Dis."},{"issue":"1","key":"76_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41392-023-01688-x","volume":"9","author":"M Zhang","year":"2024","unstructured":"Zhang M, Liu Q, Meng H, et al. Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2024;9(1):12.","journal-title":"Signal Transduct Target Ther."},{"issue":"1","key":"76_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10741-019-09831-z","volume":"25","author":"BR Pagliaro","year":"2020","unstructured":"Pagliaro BR, Cannata F, Stefanini GG, et al. Myocardial ischemia and coronary disease in heart failure. Heart Fail Rev. 2020;25(1):53\u201365.","journal-title":"Heart Fail Rev."},{"issue":"5","key":"76_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41422-022-00653-7","volume":"32","author":"D Tang","year":"2022","unstructured":"Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022;32(5):417\u2013418.","journal-title":"Cell Res."},{"issue":"2","key":"76_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41419-023-05639-w","volume":"14","author":"X Chen","year":"2023","unstructured":"Chen X, Cai Q, Liang R, et al. Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies. Cell Death Dis. 2023;14(2):105.","journal-title":"Cell Death Dis."},{"issue":"6587","key":"76_CR27","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Sci. 2022;375(6587):1254\u20131261.","journal-title":"Sci."},{"issue":"8","key":"76_CR28","first-page":"2175","volume":"19","author":"LM Ruiz","year":"2021","unstructured":"Ruiz LM, Libedinsky A and Elorza AA. Role of Copper on Mitochondrial Function and Metabolism. Autophagy. 2021;19(8):2175-2195.","journal-title":"Autophagy."},{"key":"76_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfa.2023.133135","volume":"684","author":"Z Liu","year":"2024","unstructured":"Liu Z, Ge X, Wang Y, et al. Enhancing the Fenton-like reactions performance of copper-iron oxide by inducing a lower valence state using oxidized g-C3N4 support. Colloids Surf A Physico Chem Eng Asp. 2024;684:133135.","journal-title":"Colloids Surf A Physicochem Eng Aspects."},{"issue":"5","key":"76_CR30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/cells12050798","volume":"12","author":"A Yfantis","year":"2023","unstructured":"Yfantis A, Mylonis I, Chachami G, et al. Transcriptional Response to Hypoxia: The Role of HIF-1-Associated Co-Regulators. Cells. 2023;12(5):798.","journal-title":"Cells."},{"key":"76_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110808","volume":"387","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Ha W, et al. HIF-1\u03b1: A potential therapeutic opportunity in renal fibrosis. Chem Biol Interact. 2024;387:110808.","journal-title":"Chem Biol Interact."},{"issue":"2","key":"76_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12079-020-00553-8","volume":"14","author":"R Valle-Tenney","year":"2020","unstructured":"Valle-Tenney R, Rebolledo D, Acu\u00f1a MJ, et al. HIF-hypoxia signaling in skeletal muscle physiology and fibrosis. J Cell Commun Signal. 2020;14(2):147\u2013158.","journal-title":"J Cell Commun Signal."},{"issue":"1","key":"76_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/cvr\/cvz064","volume":"116","author":"X Yan","year":"2020","unstructured":"Yan X, Zhao R, Feng X, et al. Sialyltransferase7A promotes angiotensin II-induced cardiomyocyte hypertrophy via HIF-1\u03b1-TAK1 signalling pathway. Cardiovasc Res. 2020;116(1):114\u2013126.","journal-title":"Cardiovasc Res."},{"issue":"8","key":"76_CR34","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/jcmm.12551","volume":"19","author":"X Sui","year":"2015","unstructured":"Sui X, Wei H, Wang D. Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-\u03b21 and HIF-1\u03b1 in Ang II-mediated fibrosis after myocardial infarction. J Cell Mol Med. 2015;19(8):1773\u20131782.","journal-title":"J Cell Mol Med."}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00076-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-025-00076-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00076-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T15:27:03Z","timestamp":1758727623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-025-00076-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1007\/s11596-025-00076-6","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This study was approved by the Experimental Animal Ethics Committee of Fujian Anburui Biotechnology (Approval No: IACUCFJABR2023026053). The experimental animal license number: SYXK (Min) 2022\u20130002.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors have given their consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}